After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked ...

Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves—insights ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

An unusual DNA structure may hold the key to treating one of the deadliest cancers affecting women, which claims more than ...

Early fallopian tube cell changes were found in a high‑risk patient. A live tissue bank and organoid system will help explore initial ovarian cancer development. Very little is currently understood ...

Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves - insights ...

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.